Efficacy and Safety of Alpha-Blockers Plus 5-Alpha-Reductase Inhibitors for Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis

    February 2026 in “ European journal of medical research ”
    Rubing Chen, Huiyuan Shen, Chen Wang … Zulong Wang
    Studysummary This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. The Risk of Psychiatric Disorders in Finasteride Users with Benign Prostatic Hyperplasia and Androgenetic Alopecia: A Population-Based Case-Control Study Australasian Journal of Dermatology · 2024
    2. 5-Alpha Reductase Inhibitors Use in Prostatic Disease and Beyond Translational Andrology and Urology · 2023
    3. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003
    4. The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia The New England Journal of Medicine · 1996